Close Icon We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.

Pharma Intelligence is part of the Business Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Products:

Pharma Consulting

Close Icon

Hot topics

Thought leadership

Research and development strategy

Close Icon

Events

Conferences 2018

Awards

Upcoming Webinars

Webinar recordings

Close Icon

Global Search Configuration

Search Site Products & Services
Close Icon

Search by Keyword

Focus
Needs

Optimize your pharmaceutical portfolio strategy

Our pipeline data, historical metrics, deals and milestone information and forecasts arm you with the data you need to optimize your company's portfolio.

Drive commercial success

drive commerical success pharma intelligence

As a pharmaceutical company, you need to continually evaluate your disease strategy to discern gaps in your portfolio and decide whether to build or buy. Internal candidates need to be assessed against competitors’ pipelines, and assets suitable for expanding your portfolio identified. To do all this, the right data and analysis is essential.

How we can help

Our portfolio strategy solutions give you timely and accurate intelligence you can act on, including:

A wealth of expert insights gathered by our global team of more than 65 journalists and over 300 specialist analysts
The most up-to-date, comprehensive coverage of drugs, companies, epidemiology, diseases, strategy, and pricing and reimbursement trends
Sales forecasts for pipeline candidates and patient-based sales forecasts from surveys of more than 200 physicians per indication
Country-specific treatment algorithms and reimbursement scenarios
Comprehensive and timely market research reports to help you understand macro trends and synthesize key insights so the ‘big picture’ always informs your commercial decisions
Our Ask-the-Analyst™ service that puts you in direct contact with our global analyst team

Relevant products

Datamonitor Healthcare: data analysis and insight

Datamonitor Healthcare's expert coverage of key diseases, companies, drugs and market trends makes it the go-to product for pharmaceutical and biotechnology companies to support the development and validation of their strategic plans and commercial decisions.

Key benefits:

Prioritize market opportunities
Identify unmet needs
Make informed decisions

Pharmapremia: Benchmark better and optimize your drug development pipeline

Using a peer-reviewed methodology that provides robust, unbiased drug phase success rates and timeline metrics by treatment indication, Pharmapremia enables you to make strong, informed decisions about your drug development pipeline.

Key benefits:

Manage portfolio risks
Analyze success factors
Create meaningful benchmarks

In Vivo: strategic insights for life sciences decision-makers

In Vivo offers comprehensive coverage of the global medical industry’s competitive landscape.

Key benefits:

Cutting edge thought leadership
Expert analysis
Hear from news makers

Datamonitor Healthcare

Neuropathic Pain Market and Forecast Analysis to 2026

By Nicola Sawalhi-Leckenby 07 Sep 2018

Big changes are coming to the neuropathic pain market – are you prepared? Take a look at the projected neuropathic pain drug sales for the US, Japan, and five EU nations with the latest infographic from Datamonitor Healthcare. This snapshot view of the future of the neuropathic pain market is packed with data from the full Datamonitor Healthcare Neuropathic Pain Disease Coverage report.

View infographic
In Vivo

Broader Capabilities Keep Consort On Top At Device End Of Drug Delivery

By Ashley Yeo 06 Sep 2018

Drug delivery technology specialist Consort Medical has capitalized on device respiratory expertise for 50 years, but a renewed focus on strategic expansion has seen it make an IP play, move into the pharma side and target other delivery formats for global pharma industry customers. Its enhanced capabilities will keep rivals on their toes.

Topic Drug review Drug approval

View article
Datamonitor Healthcare

Meningococcal Vaccines Forecast Infographic

By Karolina Kujawa 28 Aug 2018

Over 1.2 million cases of bacterial meningitis are estimated to occur worldwide each year. If not treated promptly, up to half of those cases will be fatal. This infographic from Datamonitor Healthcare provides a snapshot of the meningococcal vaccines market in the US and five major EU markets. What does the meningococcal vaccines market have in store and how will it affect your business? Download now.

Topic Vaccines

View infographic
Datamonitor Healthcare

Epidiolex and Epilepsy - big changes for medical marijuana

By Stephanie Yip 28 Aug 2018

With the FDA’s landmark approval of Epidiolex, a cannabidiol used to treat rare, severe pediatric epilepsies, the only obstacle to the legal sale of the drug is DEA reclassification of cannabidiol (CBD). With reclassification likely in the next 90 days, what does it mean for the epilepsy market, as well as the wider market for CBD?

Topic Drug approval

View white paper
Datamonitor Healthcare

Japan Pharma Outlook 2027 Report Extract

27 Aug 2018

Download your complimentary Japan Pharma Outlook 2027 report extract. The 16-page excerpt includes highlights from the full report, which is available to subscribers of Datamonitor Healthcare, and available to purchase on our Report Store. Discover now the complex challenges and opportunities facing Japan Pharma.

Single report
Datamonitor Healthcare

Trends in Gene Therapy Seminar

By Patricia Reilly 22 Aug 2018

The promises of gene therapy are taking a long time to be fulfilled, in part due to challenges in developing gene vectors capable of safe and efficient delivery of therapeutic genes (transgenes) into patients’ cells. Nonetheless, these challenges are being addressed in innovative ways. A variety of first-generation vectors, both viral and non-viral, have been employed in clinical trials with varying degrees of success, and the experience gained is guiding the design of next-generation vectors.

Full video
In Vivo

World In Motion The Shape Of The New Health Care Technology Ecosystem In 2022

By Ashley Yeo 22 Aug 2018

The health products industry, methods of care delivery and even the public's expectations for improved tools to prevent, monitor and treat disease have transformed dramatically in the past five years. The changes anticipated over a similar period ahead are potentially even more marked, with business continuity impacts for medtech and pharma concerns, according to Deloitte LLP experts who were on the circuit at health care industry events in Germany and the UK this spring.

Topic Business strategies Digital Health

View article
Datamonitor Healthcare

Podcast - Analyst Opinion on Approval of AndexXa for reversal of Eliquis and Xarelto

By Zachary McLellan 22 Aug 2018

Zach McLellan, Jack Allen, and guest analyst Cameron Findlater discuss current events in the healthcare space in the Datamonitor Healthcare Analyst Podcast, including the approval of AndexXa for reversal of Eliquis and Xarelto & Eli Lilly's acquisition of ARMO Biosciences.

Full podcast
In Vivo

Pharma’s New R&D Models: Federating Innovation

By Melanie Senior 22 Aug 2018

Experiments are underway to solve pharma’s well-documented R&D productivity crisis. The industry is no longer focused only on buying new drugs via M&A, or on outsourcing discovery. Companies are also building new channels through which to access innovation, setting up different kinds of partnerships, and using new kinds of data. The shift involves re-thinking pharma’s place in healthcare.

Topic Research Drug development landscape

View article
Datamonitor Healthcare

Japan Pharma Outlook Webinar Recording

By Ian Haydock 22 Aug 2018

Listen to this insightful presentation of the unique challenges and opportunities faced by Japan Pharma, hosted by the expert analysts from Pharma Intelligence.

Topic Drug development landscape

Full video
In Vivo

Ortho Demand Pull: DePuy Synthes Shaping Its Digital And Robotic Surgery Strategy Around Patient Needs

By Ashley Yeo 22 Aug 2018

Johnson & Johnson's DePuy Synthes orthopedic business has taken a measured view of digital and robotic capabilities, rather than acquiring assets that perhaps do not fully meet its strategic needs. For the business's global R&D head Euan Thomson, any new technology must augment the group's abilities to drive meaningful outcomes.

Topic Digital Health

View article
Datamonitor Healthcare

Datamonitor Healthcare Analyst Podcast: Post-ASCO Podcast 2

By Jack Allen 22 Aug 2018

Zach McLellan and Jack Allen are joined by guest analyst Maria Berezina. The group discusses key recent events that occurred at the American Society of Clinical Oncology 2018 Annual Meeting.

Topic Cancer

Full podcast
Datamonitor Healthcare

Datamonitor Healthcare Analyst Podcast: Post-ASCO Podcast 1

By Jack Allen 22 Aug 2018

Zach McLellan and Jack Allen are joined by guest analysts Dominique Fontanilla and Hardik Patel. The group discusses key recent events that occurred at the American Society of Clinical Oncology 2018 Annual Meeting.

Topic Cancer

Full podcast
In Vivo

Bayer’s US Playbook: The Smart Way To Top-Line Growth

By William Looney 22 Aug 2018

The hotly contested US market is central to Bayer’s aspirations to become a global innovation player in pharmaceuticals, especially in key growth segments like oncology. A little more than one year in, Bayer Pharmaceuticals Americas President Dr. Carsten Brunn reflects on his unit’s progress.

Topic Business strategies Company analysis

View article
In Vivo

Back To The Future: Novo’s Sørensen Reflects On CEO Years And Tasks Ahead For Industry

By Lucie Ellis 22 Aug 2018

Lars Rebien Sørensen scrutinizes the pharmaceutical industry and shares with In Vivo his vision for the future of the Novo Nordisk Foundation. With 16 years as CEO of Novo Nordisk under his belt, as well as many more years in leadership roles at the Danish company, Sørensen reflects on the past and gives his predictions for the future of the innovative drug development sector.

Topic Drug development landscape Business strategies

View article

Latest headlines

In Vivo

17 Oct 2018

VistaGen Stocks Neuropsychiatry Pipeline And Takes Aim At Depression Market

Link
In Vivo

17 Oct 2018

Deals In Depth: August 2018

Link
In Vivo

15 Oct 2018

Aetion: Sealing The Deal With Payers On Real-World Research

Link
In Vivo

15 Oct 2018

As Humira Biosimilars Arrive, Battle Lines Shift From Education To Sustainability

Link
In Vivo

10 Oct 2018

A Chance To Own The Venous Space: BTG Acquires Novate

Link
In Vivo

08 Oct 2018

A Phoenix Turn For Tonix: Rising From Phase III Ashes With New PTSD Approach

Link
In Vivo

25 Sep 2018

Execs On The Move, Sept 2018

Link
In Vivo

24 Sep 2018

Deals Shaping The Medical Industry, September 2018

Link
In Vivo

24 Sep 2018

Partnering In Cell And Gene Therapy Is A Unique Endeavor

Link
In Vivo

18 Sep 2018

Gene Therapy: Spark Charts A Course From Science To Payer And Patient Satisfaction

Link
In Vivo

18 Sep 2018

Spark Therapeutics: Calculating The Price Of A Cure

Link
In Vivo

18 Sep 2018

Aptar's Focus On Digital Connectivity Presents New Drug Delivery Opportunities

Link
In Vivo

17 Sep 2018

Drug Delivery Outsourcing In A World Of Pharma’s Shifting Sands

Link
In Vivo

17 Sep 2018

Bringing The Clinician's Rationale Into The Heart Of Strategic Decision-Making At Boston Scientific

Link
In Vivo

11 Sep 2018

INFOGRAPHIC: Drug Delivery Trends Across The Biopharma Pipeline

Link

Next steps

Request a live demo

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Request a free demo

How can we help you?

Our team is always happy to hear from you. Please call us at:

US Toll-Free : +1 888 670 8900
US Toll : +1 908 547 2200
UK & Europe : +44 (20) 337 73737
Australia : +61 2 8705 6907
Japan : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Optimize your pharmaceutical portfolio strategy

​Drive commercial success

Relevant products

Below are the Product List

Datamonitor Healthcare: data analysis and insight

Pharmapremia: Benchmark better and optimize your drug development pipeline

In Vivo: strategic insights for life sciences decision-makers

Pharma Intelligence latest insights

Latest headlines

Next steps

This is Contactus Section

Request a live demo

How can we help you?

Pharma Report Store

Drive commercial success